Wuxi apptec "successfully joined" the 100000 genome project in the UK

Source: bioprospecting on June 4, 2015, genomics England announced that four companies were selected to participate in the analysis and interpretation of the genome data of the first 8000 patients in the 100000 genome project in the UK Among them, congenica and omicia will work on the analysis of rare diseases, nanthealth is for cancer analysis, and the most well-known medicine Kant Wuxi NextCode covers both rare diseases and cancer The selected company must pass a test phase and is expected to provide services from August 1 this year Each company must provide services in the genomics England data center to ensure that data does not leave the center This phase of the project is expected to be completed within 12 months Wuxi NextCode joined the UK's 100000 genome project on January 11, 2015 Wuxi apptec announced to acquire NextCode health with $65 million in cash, and plans to merge it with the company's existing gene center to establish a new company, Wuxi NextCode genomics In addition, Wuxi apptec Gene Center was founded in 2011, which is the only clinical genomics laboratory in China certified by CLIA of the United States "The choice of genomics England is an important recognition of Wuxi NextCode technology," said Hannes smarason, co-founder and chief operating officer of Wuxi NextCode From medical diagnosis to population research, to promoting better drug research and development, our system will be applied to all aspects of the genomics England project We also look forward to providing a more comprehensive service for genomics England in the future " What is the 100000 genome project? The 100000 genome project was proposed by British Prime Minister David Cameron in December 2012 and implemented by genomics England It plans to sequence 100000 patients in the national health service outside 2017 The program kicked off in the spring of 2014 and attracted 28 companies that wanted to participate Each company obtained the genomes of 15 rare diseases and 10 cancer / normal human samples and analyzed them The reports submitted were evaluated by a team in genomics England The first 10 companies entered the next stage, bidding for the first 8000 patient gene analysis services Genomics England plans to use the experience learned at this stage to determine the clinical resolution service to be started in early 2016 At the same time, genomics England will further expand its cooperation with instrument suppliers to explore the multiple challenges of bioinformatics in sequencing and clinical analysis.